ARGENX SE (ARGX) Form 6-K — Jun 3, 2026
argenx SE presented new clinical data for efgartigimod in myositis and Sjogren’s disease at the EULAR 2026 Congress, showing sustained patient benefit and a consistent safety profile. In the ALKIVIA+ myositis study, 37.5% of patients on continuous treatment maintained major improvement at 52 weeks, with a mean Total Improvement Score of 52.19. In the RHO+ Sjogren’s disease study, patients switching to biweekly dosing maintained response, with median ClinESSDAI scores of 2.5, indicating low disease activity. A cross-indication safety analysis across 834 patients and over 1,300 patient-years confirmed no new safety signals.
Key figures
- Patient years follow up
- 1300+
- Myositis mean tis switch
- 49.62
- Myositis mean tis continuous
- 52.19
- Total patients safety analysis
- 834
- Sjogrens median clinessdai switch
- 2.0
- Sjogrens median clinessdai efgartigimod
- 2.5
- Myositis patients major improvement switch
- 33.3%
- Myositis patients major improvement continuous
- 37.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.